ReviewCureus2025
Molecular Mechanisms of Glucocorticoid Action in Migraine: A Systematic Review of Neuroinflammatory and Vascular Pathways.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a prevalent neurological disorder with complex pathophysiology that involves neurogenic inflammation, vasodilation, and hypersensitization of the trigeminovascular system. Recently, glucocorticoids have attracted attention as adjunctive treatments for migraine, mainly in refractory or recurrent attacks. Although they are traditionally recognized for their anti-inflammatory effects, the specific molecular mechanisms by which glucocorticoids alleviate migraine symptoms are not yet fully understood. In this study, we systematically reviewed the literature from 2004 to 2024 to evaluate the molecular mechanisms by which glucocorticoids exert their therapeutic effects in migraine. The analysis focused mainly on their impact on neuroinflammatory mediators, the integrity of the blood-brain barrier, and nociceptive signaling. Results from 26 selected articles showed that glucocorticoids decreased the expression of matrix metalloproteinase-9 (MMP-9), inhibited nitric oxide synthesis, and reduced calcitonin gene-related peptide (CGRP) levels, all of which are key agents implicated in migraine pathogenesis. Furthermore, glucocorticoids modulate transcription factors such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and activator protein 1 (AP-1), reduce the production of pro-inflammatory cytokines like interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α), and limit prostaglandin synthesis via cyclooxygenase-2 (COX-2) inhibition. These pathways suppress central and peripheral sensitization, which provides symptom relief. Our findings suggest that glucocorticoids play a more significant role in migraine management than previously appreciated. This influences neuroimmune responses and vascular permeability. These insights state the therapeutic potential of glucocorticoids beyond general inflammation control and encourage more targeted clinical use. This is especially true in cases with neuroinflammatory features.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.